1. Home
  2. KPTI vs INTT Comparison

KPTI vs INTT Comparison

Compare KPTI & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • INTT
  • Stock Information
  • Founded
  • KPTI 2008
  • INTT 1981
  • Country
  • KPTI United States
  • INTT United States
  • Employees
  • KPTI 325
  • INTT N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • INTT Semiconductors
  • Sector
  • KPTI Health Care
  • INTT Technology
  • Exchange
  • KPTI Nasdaq
  • INTT Nasdaq
  • Market Cap
  • KPTI 105.9M
  • INTT 93.6M
  • IPO Year
  • KPTI 2013
  • INTT 1997
  • Fundamental
  • Price
  • KPTI $0.85
  • INTT $7.68
  • Analyst Decision
  • KPTI Strong Buy
  • INTT Buy
  • Analyst Count
  • KPTI 4
  • INTT 2
  • Target Price
  • KPTI $5.00
  • INTT $14.50
  • AVG Volume (30 Days)
  • KPTI 1.1M
  • INTT 44.5K
  • Earning Date
  • KPTI 11-05-2024
  • INTT 11-01-2024
  • Dividend Yield
  • KPTI N/A
  • INTT N/A
  • EPS Growth
  • KPTI N/A
  • INTT N/A
  • EPS
  • KPTI N/A
  • INTT 0.22
  • Revenue
  • KPTI $148,442,000.00
  • INTT $121,971,000.00
  • Revenue This Year
  • KPTI $6.67
  • INTT $7.93
  • Revenue Next Year
  • KPTI $8.58
  • INTT $5.15
  • P/E Ratio
  • KPTI N/A
  • INTT $34.26
  • Revenue Growth
  • KPTI 1.77
  • INTT N/A
  • 52 Week Low
  • KPTI $0.62
  • INTT $6.28
  • 52 Week High
  • KPTI $1.95
  • INTT $14.35
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 50.60
  • INTT 53.92
  • Support Level
  • KPTI $0.75
  • INTT $6.95
  • Resistance Level
  • KPTI $0.95
  • INTT $7.94
  • Average True Range (ATR)
  • KPTI 0.07
  • INTT 0.36
  • MACD
  • KPTI -0.01
  • INTT -0.02
  • Stochastic Oscillator
  • KPTI 46.97
  • INTT 48.34

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About INTT inTest Corporation

inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). They operate their business worldwide and sells its products both domestically and internationally.

Share on Social Networks: